R1 Therapeutics Raises $77.5m Series A To Fund Development Of Kidney Disease Therapy AP306

 
• By Sushmita Panda
  
Kidney issues
The treatment of hyperphosphatemia is an important component in managing CKD patients, especially those on dialysis. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business